SUVN I6107
Alternative Names: SUVN-I6107Latest Information Update: 28 Sep 2023
At a glance
- Originator Suven Life Sciences
- Class Antidementias
- Mechanism of Action Muscarinic M1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in India (PO)
- 15 Sep 2021 SUVN I6107 is still in preclinical trials for Alzheimer's disease in India
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in India (PO)